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ABSTRACT
Background Genetically engineered virus- specific 
T cells (VSTs) are a platform for adoptive cell therapy 
after allogeneic hematopoietic stem cell transplantation. 
However, redirection to a tumor- associated antigen by 
the introduction of a transgenic T- cell receptor (TCR) 
reduces anti- viral activity, thereby impeding the possibility 
of preventing or treating two distinct complications—
malignant relapse and viral infection—with a single 
cell therapy product. Availability of CD8αβ co- receptor 
molecules can significantly impact class I restricted T- cell 
activation, and thus, we interrogated whether transgenic 
CD8αβ improves anti- viral activity mediated by native 
VSTs with or without a co- expressed transgenic TCR 
(TCR8).
Methods Our existing clinical VST manufacturing 
platform was adapted and validated to engineer TCR+ or 
TCR8+ VSTs targeting cytomegalovirus and Epstein- Barr 
virus. Simultaneous anti- viral and anti- tumor function of 
engineered VSTs was assessed in vitro and in vivo. We 
used pentamer staining, interferon (IFN)-γ enzyme- linked 
immunospot (ELISpot), intracellular cytokine staining (ICS), 
cytotoxicity assays, co- cultures, and cytokine secretion 
assays for the in vitro characterization. The in vivo anti- 
tumor function was assessed in a leukemia xenograft 
mouse model.
Results Both transgenic CD8αβ alone and TCR8 had 
significant impact on the anti- viral function of engineered 
VSTs, and TCR8+ VSTs had comparable anti- viral activity 
as non- engineered VSTs as determined by IFN-γ ELISpot, 
ICS and cytotoxicity assays. TCR8- engineered VSTs had 
improved anti- tumor function and greater effector cytokine 
production in vitro, as well as enhanced anti- tumor 
function against leukemia xenografts in mice.
Conclusion Incorporation of transgenic CD8αβ into 
vectors for TCR- targetable antigens preserves anti- viral 
activity of TCR transgenic VSTs while simultaneously 
supporting tumor- directed activity mediated by a 
transgenic TCR. Our approach may provide clinical benefit 
in preventing and treating viral infections and malignant 
relapse post- transplant.
INTRODUCTION
Malignant relapse and viral infections are 
the two major causes for treatment failure 
and morbidity in patients after allogeneic 
hematopoietic stem cell transplantation 
(HSCT).1 An ideal cellular therapy after 
stem cell transplant would therefore target 
both problems simultaneously. Virus- specific 
T cells (VSTs) are already a clinically vali-
dated immune effector cell therapy platform 
amenable to genetic redirection of antigen- 
specificity to tumor- associated antigens, as 
demonstrated with chimeric antigen receptor 
(CAR)- modified VST cell therapies.2–6 CAR+ 
VSTs can significantly re- expand in vivo upon 
viral reactivation and stimulation through 
the endogenous T- cell receptor (TCR) and 
persist long- term.6
Efforts to redirect VSTs to tumor by intro-
duction of a transgenic TCR,7–11 however, 
have been more problematic. Forced expres-
sion of a transgenic TCR leads to downregu-
lation of endogenous TCRs12 and consequent 
reduction in anti- viral reactivity, although 
anti- tumor activity can be sustained.7–11 The 
reduction in anti- viral activity was consistent 
across several studies by independent groups, 
using a variety of different VST platforms, 
TCR specificities and vectors. Anti- tumor 
function predominated consistently,10 11 or 
reactivities shifted between compartments 
depending on the type of antigen encoun-
tered (viral versus tumor antigen).11 These 
effects are most likely explained by competi-
tion for TCR/CD3/CD8 complex signaling 
components used by both the endogenous 
anti- viral and introduced transgenic TCRs, as 
well as TCR mis- pairing between introduced 
and endogenous TCR chains,11–13 and imply 
two important points: (i) the clinical benefit 
from controlling viral reactivation post trans-
plant may be jeopardized when using TCR+ 
VSTs, and (ii) the capacity of TCR+ VSTs to 
re- expand in vivo upon viral reactivation or 
vaccination may be limited compared to 
CAR+ VSTs.
Incorporation of CD8αβ into the trans-
genic TCR vector enhances the function of 
polyclonal TCR+ T cells through multiple 
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pathways,14 and here we investigated if this strategy 
rescues endogenous class I restricted anti- viral TCR 
function. We used a CD8- dependent TCR targeting 
the tumor- associated antigen survivin in the context of 
HLA- A*02:01 and expressed the TCR alone (TCR)15 or 
in combination with CD8αβ (TCR8)14 in VSTs targeting 
cytomegalovirus (CMV) and Epstein- Barr virus (EBV). 
We consistently generated TCR+ and TCR8+ VSTs with 
a predominant central memory phenotype and showed 
that anti- viral reactivities were restored in TCR8+ VSTs 
while anti- tumor function was retained.
MATERIALS AND METHODS
Cell lines
BV173 and K562 cell lines were obtained from the 
German Cell Culture Collection (DSMZ) and the Amer-
ican Type Culture Collection (ATCC), respectively, and 
maintained in complete RPMI 1640 media (Hyclone; 
Thermo Scientific) supplemented with 10% or 20% 
fetal bovine serum (FBS, Hyclone), 1% penicillin- 
streptomycin (Gibco), and 1% glutamax (Gibco). Two 
hundred and ninety- three T cells (ATCC) were main-
tained in complete IMDM media (Hyclone) containing 
10% FBS, 1% penicillin- streptomycin, and 1% glutamax. 
For the mouse xenograft experiments, the previously 
described BV173.ffLuc cell line was used.15
Blood samples from healthy donors
Buffy coats were obtained from CMV seropositive 
de- identified healthy human volunteers at the Gulf 
Coast Regional Blood Center (Houston, Texas, USA). 
HLA- A2 status was assessed by fluorescence- activated 
cell sorting (FACS) analysis and HLA- A2+ donors were 
selected for the experiments.
Generation of retroviral vectors and supernatants
The retroviral vectors expressing the survivin- specific 
(s24) TCR and the combination of TCR and CD8αβ 
have previously been described.14 15 Genes encoding for 
the human CD8α (Uniprot P01732) and CD8β isoform 
1 (βM1, Uniprot P10966-1) chains, separated by a 2A 
sequence, were synthesized by Geneart (Invitrogen) 
and cloned into the SFG retroviral vector backbone 
(figure 1A) (In- Fusion HD Cloning Kit, Clontech). 
Transient retroviral supernatants were prepared by 
co- transfection of 293 T cells with RD114 and Pegpam 
plasmids and the SFG vector containing the gene of 
interest.16
Generation of gene-modified virus-specific T cells
Peripheral blood mononuclear cells (PBMCs) were 
isolated from buffy coats using density gradient centrif-
ugation by Lymphoprep (Accurate Chemical and 
Scientific Corporation). CD14+ monocytes were posi-
tively selected from PBMCs with microbeads (Miltenyi 
Biotech) and grown in serum- free CellGenix dendritic 
cell (DC) media (CellGenix) supplemented with 
1000 U/mL of Interleukin (IL) 4 and granulocyte- 
macrophage colony- stimulating factor (GM- CSF) each 
(Miltenyi) for 5 to 7 days to generate immature DCs. DCs 
were matured using a cocktail of cytokines, including 
IL4 (1000 U/mL), GM- CSF (800 U/mL), IL1β (10 ng/
mL), tumor necrosis factor (TNF)-α (10 ng/mL), IL6 
(100 ng/mL), and prostaglandin E2 (1 µg/mL), all 
from R&D Systems for 48 hours. For antigen pulsing, 
mature DCs were incubated for 60 min at 37°C with a 
mixture of CMV and EBV pepmixes (CMV pp65, CMV 
IE1, EBV LMP2, EBV BZLF1, EBV EBNA 1, all from JPT 
Technologies; 1 µg/mL), and HLA- A*02:01- restricted 
immunodominant peptides (CMV pp65- derived NLV 
(NLVPMVATV, 1 µg/mL), immediate early EBV BRLF1- 
derived YVL (YVLDHLIVV, 1 µg/mL), early EBV 
BMLF1- derived GLC (GLCTLVAML, 1 µg/mL), all from 
Genemed Synthesis.17 The combination of pepmixes 
and peptides was chosen based on antigen expression 
patterns of CMV and EBV infection in the post trans-
plant period.18 19 Autologous PBMCs were thawed and 
stimulated with pepmix/peptide- pulsed mature DCs 
(E:T ratio 20:1) in T- cell media (1:1 mixture of RPMI 
1640 and Click’s media, Hyclone), supplemented with 
10% FBS (Hyclone), 1% penicillin- streptomycin, 1% 
glutamax and cytokines IL7 (10 ng/mL, R&D Systems), 
IL15 (10 ng/mL, R&D Systems), and IL21 (30 ng/
mL, R&D Systems). On day 3, antigen- primed cells 
were harvested and retrovirally transduced for 2 to 3 
days with the retroviral supernatants for TCR, TCR8, 
or CD8αβ on retronectin- coated plates or exposed to 
retronectin- coated plates without viral particles (for 
non- transduced VSTs). After transduction, cells were 
further expanded for 7 to 9 days in culture flasks or 
GRex gas permeable culture devices (Wilson Wolf, St. 
Paul, USA). A second stimulation was performed with 
pepmix/peptide- pulsed irradiated (40 Gy) autologous 
activated T cells (previously activated on OKT3/anti- 
CD28- coated plates) and irradiated (100 Gy) K562cs 
cells (K562 cells engineered to express CD80, CD83, 
CD86, 41BBL, and CD32) at a ratio of 1:1:5 as previ-
ously described,20 in T- cell media and cytokines IL7 
(10 ng/mL), IL15 (10 ng/mL), and IL21 (30 ng/mL). 
For the second stimulation, the HLA- A*02:01- restricted 
survivin peptide LMLGEFLKL (Genemed Synthesis) 
that is recognized by the transgenic TCR was also 
included in the mixture. The method is good manufac-
turing practice (GMP) compatible.
Immunophenotyping
Cell surface stainings were performed with fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), allophycocy-
anin (APC), V450, PerCP, APC- AF750, or krome orange- 
conjugated antibodies against CD4, CD8, CD45RO, 
CD62L, CCR7, CD45RA, CD56, TCR γδ, CD271, CD19, 
7- AAD (BD Biosciences), murine TCRβ constant region 
(eBioscience), survivin dextramer (Immudex), or 
NLV pentamer (Proimmune) for 30 min at 4°C. For 
the degranulation assay, VSTs (106) were treated with 
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golgiplug/brefeldin A (Invitrogen) and CD107a/b 
VioBlue (BD Biosciences) followed by appropriate stim-
ulations: CMV/EBV- specific viral pepmixes or single 
peptide (pp65, IE1, LMP2, BZLF1, EBNA1, and GLC), 
survivin- specific LML peptide, viral pepmixes/peptide 
plus LML peptide, PMA (25 ng/mL)/ionomycin (1 µg/
mL), or control influenza matrix protein GIL (GILG-
FVFTL, Genemed Synthesis) peptide (negative control) 
in T- cell media for 4 hours at 37°C. Intracellular staining 
was performed using anti- human interferon (IFN)-γ-
FITC and TNF-α-PE (BD Biosciences). All samples were 
acquired on a FACS Canto with BD FACSDiva, and anal-
ysis was performed using FlowJo software (Tree Star).
IFN-γ ELISpot
For the IFN-γ enzyme- linked immunospot (ELISpot) 
assay, 105 VSTs per well were plated in triplicates and 
stimulated with individual pepmixes/peptides (1 µg/
mL) or cell lines (BV173 or K562) at 1:1 ratio (105 
cells per well) or media alone. Plates were incubated at 
37 °C/5% CO2 overnight and developed as previously 
described.15 Spot forming units were enumerated by 
ZellNet.
Co-culture assay and cytokine detection
VSTs and BV173 cells were co- cultured at E:T ratio 
1:5 in the absence of exogenous cytokines. Co- culture 
Figure 1 Generation and characterization of TCR+ and TCR8+ VSTs. (A) Schemes of retroviral vectors used in the study. (B) 
Scheme of transgenic VST production. S1: first stimulation, S2: second stimulation. (C) Transduction efficiencies of VSTs with 
TCR (red dots) or TCR8 (blue dots) vectors compared with NT controls (gated on live cells, %mTCR+ cells, n=9, mean±SD). 
(D) CD8α mean fluorescence intensity in VSTs (n=9, mean±SD). (E) Fold expansion of NT (white), TCR+ (red) and TCR8+ (blue) 
VSTs after S1 and S2 (n=9, mean±SD, p=ns). (F) Distribution of CD4+, CD8+, NK (CD56+ CD3−) or TCRγδ (TCRγδ+ CD3+) cells 
in NT, TCR+ and TCR8+ VSTs (n=5, mean±SD, p=ns). (G) Memory phenotype: TN, TCM, TEM, and TEFF subset distribution in NT or 
transduced VSTs based on two- marker CD45RO/CD62L gating (n=5, mean±SD, one- way analysis of variance). CD4+ TN: NT 
versus TCR8+: *p=0.03; TCR+ versus TCR8+: **p=0.008. CD4+ TCM: NT versus TCR8+: *p=0.03; TCR+ versus TCR8+: p=ns. (A 
to F) Coding of significance levels: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CMV, cytomegalovirus; DC, dendritic cell; EBV, 
Epstein- Barr virus; NT, non- transduced; PBMC, peripheral blood mononuclear cell; TCR, T- cell receptor; VSTs, virus- specific T 
cells.
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supernatants were harvested 24 hours after plating and 
stored at −80°C for cytokine analysis. Residual VSTs 
and tumor cells were enumerated after 3 days using 
CountBright Beads (Life Technologies) and FACS anal-
ysis. Cytokines were quantified in supernatants using 
the MILLIPLEX Human CD8+ T cells magnetic beads 
panel (EMD Millipore) and a Luminex 200 instrument 
(Luminex).
51Chromium release assay
To assess the short term in vitro cytotoxic function of 
VSTs, a standard 51Chromium (51Cr) release assay was 
performed.15 Autologous activated T cells were used as 
targets, pulsed with the indicated peptides or pepmixes 
and labeled with 51Cr for 1 hour. Effector and target 
cells were incubated at various ratios. As controls, 
target cells were incubated in media alone or with 1% 
Triton- X 100 (Sigma- Aldrich) for 4 hours to determine 
the spontaneous and the maximum release. The mean 
percentage of specific lysis of triplicate wells was calcu-
lated as follows: ((test counts – spontaneous counts)/
(maximum counts − spontaneous counts))×100%.
Mouse xenograft model
Female NOD- SCID-γc−/− (NSG) mice (6 to 8 weeks 
old) were purchased from the Jackson Laboratory 
and housed at the Baylor College of Medicine Animal 
Facility. Mice were irradiated with 120 cGy and infused 
with 3×106 BV173.ffLuc cells/mouse through the tail 
vein 4 to 6 hours later. Leukemia burden was monitored 
by bioluminescent imaging (BLI) (photons/s/cm2/sr) 
using the Xenogen in vivo imaging system (Caliper Life 
Sciences). Two VST injections (2×106/mouse, 3 days 
apart) were administered through the tail vein or the 
retro- orbital vein plexus beginning 24 hours after tumor 
injection. Leukemia growth was monitored weekly by 
BLI and survival recorded.
Statistical analysis
Data were summarized using descriptive statistics. 
Comparisons between groups were made using student’s 
t- test, one- way or two- way analysis of variance, and 
Friedman or Wilcoxon test, whichever was appropriate 
(figure legends). Area under the curves of biolumines-
cent signal intensity were calculated in GraphPad Prism 
from day 0 to day 28 and differences between groups were 
analyzed with the Mann- Whitney test. Survival of mice 
was analyzed by Kaplan- Meier graphs and differences 
were analyzed with the log- rank test. GraphPad prism 6 
(GraphPad software, La Jolla, California) or higher was 
used for statistical analysis. P values <0.05 were consid-
ered statistically significant.
Study approval
Animal studies were reviewed and approved by the Institu-
tional Animal Care and Use Committee of Baylor College 
of Medicine.
RESULTS
Generation of TCR+ and TCR8+ transgenic VSTs with central 
memory phenotype
We used three retroviral constructs encoding for 
the TCR alone, CD8αβ alone, or the combination of 
TCR and CD8αβ (TCR8) (figure 1A). PBMCs from 
CMV- seropositive HLA- A*02:01+ donors were used 
to generate mature DCs, pulsed with CMV and EBV 
pepmixes, and used to stimulate autologous PBMCs 
in the presence of cytokines. Three days later, acti-
vated T cells were retrovirally transduced and further 
expanded for an additional 5 to 7 days. A second stim-
ulation of VSTs was performed if necessary, to further 
expand VSTs using pepmix pulsed autologous activated 
polyclonal T cells and irradiated csK562 cells (engi-
neered to express several co- stimulatory molecules) 
(figure 1B and Methods). We achieved high transduc-
tion efficiencies with both TCR and TCR8 vectors. As 
expected, TCR8 transduction was less efficient because 
of the larger vector size (%mTCR+ cells, TCR+ versus 
TCR8+: 64±17% vs 46±16%, **p=0.002, mean±SD, n=9) 
(figure 1C). We detected higher CD8α mean fluores-
cence intensity (MFI) in VSTs transduced with TCR8 
compared with TCR or NT VSTs (CD8α MFI NT versus 
TCR+: 8.9±2.4×103 vs 12.6±4.4×103, **p=0.002, TCR+ 
versus TCR8+: 12.6±4.4×103 vs 19.3±9.5×103, *p=0.03, NT 
versus TCR8+: 8.9±2.4×103 vs 19.3±9.5×103, **p=0.006, 
mean±SD, n=9) (figure 1D). VST fold expansion was 
comparable between all groups over two stimulations. 
After first stimulation and transduction, we achieved 
48±29- fold expansion for NT, 41±36- fold expan-
sion for TCR+, and 40±34- fold expansion for TCR8+ 
VSTs (mean±SD, n=6 to 8, p=ns between all groups) 
(figure 1E). With the second stimulation, all VSTs were 
further expanded for a total of 1126±979- fold expan-
sion for NT, 736±625- fold expansion for TCR+, and 
767±854- fold expansion for TCR8+ VSTs (mean±SD, 
p=ns between all groups) (figure 1E). Phenotypic 
characterization of the generated VST lines revealed a 
comparable subset composition with CD3+ CD4+, CD3+ 
CD8+ T cells, and the absence of natural killer (NK) 
cells (CD3− CD56+) or TCRγδ+ T cells between NT, 
TCR+, and TCR8+ VSTs (figure 1F). VSTs with an acti-
vated CD3+ CD56+ phenotype were increased in some 
donors in the TCR+ and TCR8+ lines, but the difference 
was not statistically significant (%CD3+ CD56+ cells 
in NT versus TCR+: 0±0% vs 13±15%, p=ns, NT versus 
TCR8+: 0±0% vs 16±19%, p=ns, TCR versus TCR8+: 
13±15% vs 16±19%, p=ns, mean±SD, n=5). Memory 
phenotyping using the two markers CD45RO and 
CD62L showed a high proportion of TCM cells in both, 
the CD8+ and the CD4+ compartment (figure 1G). In 
TCR8+ CD4+ VSTs, both the TN and the TCM compart-
ments were better preserved compared with NT CD4+ 
VSTs or TCR+ CD4+ VSTs (CD4+ TN: NT versus TCR8+: 
6.9±4.9% vs 22.0±16.8%, *p=0.03, TCR+ versus TCR8+: 
3.5±2.7% vs 22.0±16.8%, **p=0.008; CD4+TCM: NT 
versus TCR8+: 54.8±7.4% vs 70.8±16.6%, *p=0.03, TCR+ 
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versus TCR8+: 63.9±5.8% vs 70.8±16.6%, p=ns). Thus, 
we can reliably generate TCR and TCR8 transgenic VST 
lines with a predominant central memory compartment 
and retroviral transduction does not alter VST expan-
sion, cellular composition or memory phenotype. Our 
activation, transduction and expansion process is fully 
GMP compatible.
TCR8+ VSTs maintain anti-viral specificities that are 
comparable to NT VSTs
VST lines were evaluated for their NLV- specific pentamer 
staining (figure 2A) and their epitope specific IFN-γ 
and TNF-α production by ELISpot (figure 2B) and 
intracellular cytokine staining (ICS) (figure 2C) at the 
end of the first stimulation/expansion. NLV pentamer 
staining revealed a consistently and significantly 
reduced CD8α+ NLV+ population in TCR+ compared 
with NT and TCR8+ VSTs (NT versus TCR+ VSTs: 
9.66±16.8% vs 1.36±1.33%, **p=0.008; TCR+ versus 
TCR8+ VSTs: 1.36±1.33% vs 7.48±15.31%, **p=0.008; 
mean±SD, n=9). The population was restored in TCR8+ 
VSTs to levels that were slightly but statistically signifi-
cantly lower than in NT VSTs (figure 2A, NT versus 
TCR8+ VSTs: 9.66±16% vs 7.48±15.31%, *p=0.04). In 
the ELISpot and ICS, we found that TCR+ VSTs and 
TCR8+ VSTs produced comparable levels of IFN-γ 
against the cognate survivin peptide (LML) or the 
HLA- A*02:01+ survivin+ leukemia cell line BV173, but 
anti- viral reactivities against CMV (NLV peptide, pp65 
and IE1 pepmixes) and EBV (GLC and YVL peptides, 
LMP2 pepmix) were significantly reduced in TCR+ 
VSTs compared with NT VSTs. We observed the rescue 
of cytokine production, however, in TCR8+ VSTs, which 
produced higher levels of IFN-γ and TNF-α than TCR+ 
VSTs, and comparable levels as NT VSTs (figure 2B and 
C). TCR8+ VSTs also degranulated in response to the 
stimulation with the cognate antigen as efficiently as 
NT VSTs, while degranulation of TCR+ VSTs was signifi-
cantly reduced (figure 2C).
Transgenic expression of CD8αβ in VSTs enhances recognition 
of viral epitopes
To assess whether transgenic expression of CD8αβ 
enhances endogenous virus- specific TCR detection and 
function, we analyzed NLV pentamer staining and NLV- 
specific IFN-γ production of NT VSTs and CD8αβ+ VSTs. 
Expression of transgenic CD8αβ enhanced the detection 
of NLV pentamer+ VSTs at the end of the first stimula-
tion, but was not statistically significant (%NLV+ VSTs 
in NT versus CD8αβ+: 3.1±4.4% versus 12.9±15%, p=ns, 
mean±SD, n=5) (figure 3A, left and middle panel). We 
also detected a trend to increased CD8α MFI in four out 
of five donors tested (figure 3A, right panel) but this did 
not reach conventional levels of significance. However, 
the MFI of the NLV pentamer staining was signifi-
cantly higher in CD8αβ+ VSTs compared with NT VSTs 
(NLV MFI NT versus CD8αβ+: 1018±438 vs 2520±948, 
**p=0.005, mean±SD, n=5) (figure 3B). These find-
ings are consistent with previous reports assessing the 
influence of CD8 co- receptor availability on major histo-
compatibilty complex (MHC) class I multimer stainings.21 
With regards to NLV- specific T- cell responses determined 
by IFN-γ ELISpot, we found a significant increase of IFN-γ 
spot forming cells in CD8αβ+ VSTs compared with NT 
VSTs (653±246 vs 835±248, *p=0.04, mean±SD, n=3, 
plated in duplicates or triplicates) in response to the NLV 
peptide (figure 3C). Hence, forced expression of CD8αβ 
in VSTs enhances endogenous TCR function.
TCR+ and TCR8+ VSTs kill viral targets in vitro
We next assessed the cytolytic activity of NT, TCR+, and 
TCR8+ VSTs against viral antigen- presenting target cells. 
In a 4- hour 51Cr- release assay against peptide/pepmix- 
pulsed activated autologous T cells, we detected specific 
lysis of target cells pulsed either with NLV peptide or 
the pooled CMV pepmixes/peptides or the pooled EBV 
pepmixes/peptides (solid lines), while unpulsed target 
cells (dashed lines) were not killed (figure 4A, mean±SD, 
n=4, plated in duplicates or triplicates). Survivin LML 
peptide pulsed targets were killed by TCR+ and TCR8+ 
VSTs but not NT VSTs. Overall, we observed a trend for 
lower cytolytic activity against viral antigen- presenting 
targets by TCR+ VSTs compared with TCR8+ VSTs or NT 
VSTs, but the overall differences were not statistically 
significant due to high donor variability. Donor variability 
is illustrated in figure 4B where we provide a summary of 
specific target cell lysis obtained at the E:T ratio of 20:1, 
depicting individual dots per donor and average bars. 
Some donors lysed targets to a similar extent with TCR+ 
or TCR8+ VSTs (eg, donor #3, cyan), while others showed 
a significant drop when comparing NT versus TCR+ VSTs, 
and a partial restoration of the activity with TCR8+ VSTs 
(eg, donor #14, green). Overall, we found a significant 
enhancement of CMV- specific target cell lysis (both NLV 
peptide and CMV pool) with TCR8+ VSTs compared with 
TCR+ VSTs, while the analysis for the EBV pool did not 
reach significance. One donor had a weak baseline CMV 
and a strong EBV response (donor #9, purple), while the 
others had strong baseline responses against both viruses. 
Killing of LML peptide- pulsed target cells was consistent 
with both TCR+ VSTs and TCR8+ VSTs, and unpulsed 
targets were not killed.
Anti-leukemic activity of TCR+ and TCR8+ VSTs in vitro and 
in vivo
We next assessed the anti- leukemic activity of TCR+ and 
TCR8+ VSTs compared with NT VST controls in a co- cul-
ture assay with BV173 leukemia cells (HLA- A*02:01+ 
survivin+). We found significant cytotoxicity with TCR+ 
and TCR8+ VSTs by quantification of residual tumor 
cells in culture after 3 days (tumor cell count NT versus 
TCR+: 2.4±0.5×106 versus 0.04±0.1×106, **p=0.004, NT 
versus TCR8+: 2.4±0.5×106 versus 0.3±0.4×106, *p=0.04, 
TCR+ versus TCR8+: 0.04±0.1×106 vs 0.3±0.4×106, p=ns, 
mean±SD, n=6) (figure 5A). VST counts at the end of 
the co- cultures were not different between groups. Anal-
ysis of co- culture supernatants collected 24 hours after 
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Figure 2 Transgenic CD8αβ is required to preserve anti- viral specificities of TCR- transgenic VSTs. (A) Frequency of CD8α+ 
NLV+ VSTs comparing NT, TCR+, and TCR8+ VST lines by FACS. representative FACS plots (left), summary (right), n=9, 
mean±SD, Wilcoxon test. (B) IFN-γ enzyme- linked immunospot comparing NT, TCR+, and TCR8+ VSTs for their anti- viral and 
anti- tumor (survivin) activities, n=8, mean±SD, Friedman test. Each donor was plated in technical duplicates or triplicates, dots 
show mean for each donor. (C) Degranulation (CD107a/b) and intracellular cytokine staining by FACS comparing NT, TCR+, 
and TCR8+ VSTs for their anti- viral and anti- survivin- directed reactivities. Percentage of positive cells for CD107+/IFN-γ+ 
(left), CD107+/TNF-α+ (middle), or IFN-γ+ TNF-α+ (right), n=4, mean±SD, two- way analysis of variance. Influenza GIL peptide: 
negative control. (A- C) Coding of significance levels: ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CMV, 
cytomegalovirus; FACS, fluorescence- activated cell sorting; IFN, interferon; NT, non- transduced; SFC, spot- forming cells; TCR, 
T- cell receptor; TNF, tumor necrosis factor; VSTs, virus- specific T- cells.
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initial tumor challenge revealed that both TCR+ and 
TCR8+ VSTs produced significant amounts of TH1 cyto-
kines (IFN-γ NT versus TCR+: 0.6±0.4 vs 12.7±4.3 ng/
mL, **p=0.007; NT versus TCR8+: 0.6±0.4 vs 10.5±3.1 ng/
mL, p=ns; TCR+ versus TCR8+, p=ns, TNF-α NT versus 
TCR+: 0.02±0.008 vs 1.0±0.9 ng/mL, **p=0.005, NT 
versus TCR8+: 0.02±0.008 vs 0.9±0.7 ng/mL, p=ns, TCR+ 
versus TCR8+, p=ns, mean±SD, n=6) and cytotoxic gran-
ules (Granzyme B (GZMB) NT versus TCR+: 2.3±0.9 vs 
6.8±4.3 ng/mL, *p=0.03, NT versus TCR8+: 2.3±0.9 vs 
7.2±3.7 ng/mL, *p=0.03, TCR+ versus TCR8+: p=ns, 
mean±SD, n=6) (figure 5B). We also detected cytotoxic 
granule release into the supernatant of NT VSTs even 
though no (non- specific) killing activity was detectable. 
Low levels of IL10 production were detected from TCR+ 
and TCR8+ VSTs (figure 5B). To assess the anti- leukemic 
function of engineered VSTs in vivo, we used our previ-
ously established NSG xenograft model with BV173- ffLuc 
cells (figure 5C). One day after leukemia challenge, the 
mice received two infusions of NT, TCR+, or TCR8+ VSTs 
3 days apart and tumor growth was assessed over time 
by BLI. Mice treated with TCR+ and TCR8+ VSTs expe-
rienced significantly slower leukemia progression than 
mice treated with NT VSTs, indicating that both TCR+ and 
TCR8+ VSTs produced significant anti- leukemic activity 
in mice (AUC on day 28: NT versus TCR+: **p=0.008, NT 
versus TCR8+: **p=0.008, TCR+ versus TCR8+: p=0.05, 
ns, n=5 mice per group) (figure 5D and E). There was 
also a trend to better leukemia control by TCR8+ VSTs 
compared with TCR+ VSTs, although not statistically 
significant (p=0.05). The anti- leukemic activity of TCR+ 
VSTs and TCR8+ VSTs also significantly improved the 
survival of mice (NT versus TCR+: **p=0.003, NT versus 
TCR8+: **p=0.003, TCR+ versus TCR8+: p=0.05, ns, n=5 
mice per group), with again a trend to better survival with 
TCR8+ VSTs (figure 5F).
DISCUSSION
We show that transgenic CD8αβ alone or in combina-
tion with a transgenic TCR promotes endogenous TCR 
function in VSTs expressing a second transgenic TCR. 
TCR8 expression in VSTs rescues endogenous anti- viral 
activity to levels comparable to non- transduced VSTs 
while maintaining anti- tumor function mediated by the 
transgenic TCR. These benefits are observed both in vitro 
and in vivo. Thus, our approach overcomes the compe-
tition for essential signaling components that leads to 
Figure 3 Transgenic expression of CD8αβ in VSTs enhances recognition of the NLV epitope in the absence of a transgenic 
TCR. (A) NLV pentamer staining of NT or CD8αβ+ transduced VSTs. Representative fluorescence- activated cell sorting plots of 
percentage of CD8α+ NLV+ cells (left), summary (middle), CD8α MFI (right) n=5, p=ns. (B) NLV MFI on live CD8α+ NLV+ cells, 
n=5. (C) IFN-γ enzyme- linked immunospot of NT or CD8αβ+ VSTs, n=3, donors plated in duplicates or triplicates, individual 
values shown. (A–C) Coding of significance levels: ns, not significant, *p<0.05, **p<0.01. Paired t-test. IFN, interferon; MFI, 
mean fluorescence intensity; NT, non- transduced; SFCs, spot- forming cells; TCR, T- cell receptor; VSTs, virus- specific T- cells.
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downregulation of anti- viral reactivities and impedes full 
therapeutic benefit of providing anti- viral and anti- tumor 
function through endogenous and transgenic TCRs.
The concept of providing simultaneous anti- viral and 
anti- tumor function in one cell therapy product was clini-
cally validated when autologous CAR modified VSTs were 
shown to be able to target both EBV and GD2 in patients 
with neuroblastoma.2 After adoptive transfer, GD2- CAR+ 
EBVSTs demonstrated safety, anti- tumor function, and 
long- term persistence in patients.2 3 Since then, the 
approach was extended to CD19- CARs expressed in allo-
geneic stem cell donor- derived VSTs and infused to chil-
dren with high risk B- cell acute lymphoblastic leukemia 
in remission after allogeneic HSCT,4–6 in whom in vivo 
expansion of CD19- CAR+ VSTs during viral reactivation 
was observed.6 Similarly, vaccination of subjects with vari-
cella zoster virus may be another approach that augments 
expansion of VSTs expressing a GD2 CAR in patients 
with sarcoma or neuroblastoma (NCT01953900).6 
Thus, in principle, stimulation through the endogenous 
virus- specific TCR and co- stimulation on antigen- 
presenting cells in vivo can produce significant re- expan-
sion and function of infused CAR+ VSTs.
It is more challenging to extend the VST platform 
to target tumor antigens by means of transgenic TCRs 
rather than CARs. Endogenous and transgenic TCRs 
compete for the same TCR signaling complex compo-
nents (including CD3 chains and the CD8αβ co- re-
ceptor), and introduced TCR chains may mis- pair with 
endogenous TCR chains, leading to an overall reduced 
anti- viral activity.7–12 The use of murine- constant regions 
in the transgenic TCR can significantly reduce mis- 
pairing.13 Transfer of CD8αβ can redirect CD4+ T cells 
to class I- restricted antigens, and the transgenic CD4+ 
T cells become cytotoxic hybrid cells.14 22–27 We have 
recently analyzed the transcriptional consequences of 
TCR8 expression in polyclonal CD4+ and CD8+ T cells 
by single cell RNA sequencing and experimental vali-
dation and showed that transgenic TCR8 has multiple 
advantages in both CD4+ and CD8+ lineages, promoting 
Figure 4 Cytotoxicity against viral targets in vitro is better preserved in VSTs engineered with TCR8 than TCR. (A) Percentage 
of specific lysis of peptide/pepmix pulsed or unpulsed activated autologous T cells by NT, TCR+, or TCR8+ VSTs in a 4- hour 
51Cr- release assay at E:T ratio 40:1, 20:1, 10:1, 5:1, n=4, mean±SD. (B) Percentage of specific lysis at E:T ratio 20:1, depicting 
individual donors (colored lines) and average (bars). Paired t- test. ns, not significant, *p<0.05, **p<0.01. CMV, cytomegalovirus; 
EBV, Epstein- Barr virus; NT, non- transduced; TCR, T- cell receptor; VSTs, virus- specific T cells.
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Figure 5 TCR+ and TCR8+ VSTs kill leukemia in vitro and in vivo and produce TH1 cytokines. (A) Co- culture of NT, TCR+, 
or TCR8+ VSTs with BV173 leukemia cells (HLA- A*02:01+ survivin+); E:T ratio 1:5. residual BV173 (left) or VSTs (right) were 
quantified by fluorescence- activated cell sorting on day 3, n=6, mean±SD, one- way analysis of variance on log transformed 
data. (B) Cytokine production after 24 hours in co- culture, n=6, mean±SD, Friedman test. (C) Mouse xenograft model 
experimental set up. (D) Individual mouse pictures of BLI, color scale 1×105 to 1×106 photons/s/cm2/sr. (E) Summary of BLI data 
from mice treated with control (NT, black), TCR+ (red), or TCR8+ (blue) VSTs. n=5 mice per group, individual lines per mouse. 
Mann- Whitney test on area under the curves from day 0 to 28. (F) Kaplan- Meier survival analysis of mice treated with control 
(NT, black), TCR+ (red), or TCR8+ (blue) VSTs. n=5 mice per group, log- rank test. (A–F) Coding of significance levels: ns, not 
significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. BLI, bioluminescent imaging; GM- CSF, granulocyte- macrophage 
colony- stimulating factor; IFN, interferon; IL, interleukin; TCR, T- cell receptor; TNF, tumor necrosis factor; NT, non- transduced; 
VSTs, virus- specific T cells.
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an overall enhanced anti- tumor function.14 We now 
investigated the impact of transgenic CD8αβ on endog-
enous class I- restricted TCR function in CD8+ T cells as 
we hypothesized that combining CD8αβ co- receptor as 
a transgene with a tumor- targeted TCR is one potential 
means of overcoming the limitation of reduced anti- viral 
activity in TCR+ VSTs. We first confirmed that anti- viral 
specificity and activity was reduced when our survivin- 
specific TCR is expressed in VSTs. Next, we demonstrated 
that TCR8 rescued endogenous anti- viral TCR specificity 
and activity, using pentamer staining, IFN-γ ELISpot, 
degranulation assay and ICS, as well as cytotoxicity assays. 
TCR8+ VSTs retained specificity and anti- viral activity that 
was comparable to NT VSTs. We also showed that the 
transgenic CD8αβ effect on endogenous TCR function 
was preserved in vitro even in the absence of a trans-
genic TCR. These findings indicate that (i) TCR8+ VSTs 
respond to viral infections to a comparable level as NT 
VSTs, and (ii) TCR8+ VSTs are ready to re- expand on viral 
challenge. Importantly, the in vivo anti- tumor function of 
TCR8+ VSTs was retained. However, the in vivo anti- viral 
activity of TCR8+ VSTs remains to be validated, an anal-
ysis that will be a component of ongoing and proposed 
human studies.2–4 6 Several features of the CD8αβ co- re-
ceptor most likely explain our findings, including its role 
in TCR- pMHC recognition and modulation of antigen- 
sensitivity,28 recruitment of Lck to the immune synapse, 
and activation of signaling components that are crucial 
during early T- cell activation,29 and, as recently demon-
strated by single cell RNA sequencing, its impact on a 
variety of transcriptional pathways upon tumor challenge 
that support enhanced anti- tumor function.14
An additional advantage of VSTs as a platform for the 
delivery of tumor- antigen- specific T- cell function to treat 
cancer patients lies in the fact that transgenic VSTs can 
be generated from well- characterized healthy donors 
for allogeneic cell banks. Indeed, third party donor allo-
geneic ‘off- the- shelf’ banked VSTs have been clinically 
validated for the treatment of viral infections or EBV- 
associated lymphoproliferation in immunocompromised 
patients after HSCT or solid organ transplant.18 30–33 
Third party donor VSTs could be engineered with TCRs 
or CARs, banked, and thereby provide a readily available 
‘off- the shelf’ product that does not require genome 
editing for safe infusion in immunocompromised 
patients.34 Furthermore, additional engineering can be 
incorporated to protect VSTs from host NK and/or T- cell 
mediated allograft rejection, furthering their potential to 
become a safe universal ‘off- the shelf’ T- cell product with 
long in vivo persistence.35 36
Stimulation of T cells with viral peptide- pulsed autol-
ogous DCs followed by retroviral transduction yielded 
TCR+ or TCR8+ VST lines consistently composed of CD4+ 
and CD8+ VSTs with a predominant central memory 
phenotype and high transduction efficiencies. TCR8 
expression was associated with a better preservation of 
less differentiated VSTs in the CD4+ compartment.14 The 
only HLA restriction of the product is defined by the 
transgenic TCR used to redirect VSTs to the cancer. Feasi-
bility and safety of our manufacturing have already been 
demonstrated in CAR+ VST clinical trials and are GMP 
compliant.2–4 6
In summary, we show that transgenic CD8αβ rescues 
endogenous anti- viral TCR function in VSTs when 
combined with a tumor- targeted transgenic TCR. Our 
TCR8+ VST product provides significant anti- tumor 
function in vivo. We propose that the use of a combined 
TCR8 vector may better maintain in vivo long- term bene-
fits of VSTs than cells that lack this modification. Our 
clinically validated VST platform is amenable to genetic 
engineering with TCR8 and ready to clinically assess the 
safety and efficacy to prevent and treat viral infection and 
malignant relapse after allogeneic HSCT.
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